Open AccessMonoclonal antibodies that target the immunogenic proteins expressed in colorectal cancer
Author(s) -
Myron Arlen,
Philip M. Arlen,
Gene F. Coppa,
Jim Crawford,
Xueping Wang,
Olga Saric,
Alex Dubeykovskiy,
Ernesto P. Molmenti
Publication year - 2014
Publication title -
world journal of gastrointestinal oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.924
H-Index - 26
ISSN - 1948-5204
DOI - 10.4251/wjgo.v6.i6.170
Subject(s) - medicine , colorectal cancer , debulking , cancer , immunotherapy , tumor debulking , monoclonal antibody , stage (stratigraphy) , oncology , adjuvant , cancer research , chemotherapy , immunology , antibody , ovarian cancer , paleontology , biology
In an attempt to improve upon the end results obtained in treating colorectal cancer it was apparent that the earlier the diagnosis that could be obtained, the better the chance for obtaining desired results. In the case of more advanced tumors typified by later stage colorectal cancer, surgical debulking is an important part of the treatment strategy. Here the use of additional therapeutic modalities including chemotherapy and present day immunotherapy has failed to accomplish the desired improvements that have been sought after. Adjuvant therapy, has offered little to the overall survival. The concept of early detection is now recognized as the initial step in reaching proper end results and can readily be demonstrated from colorectal cancer studies. Here survival has been found to be a reflection of the stage at which the tumor is first identified and treated. When specific monoclonals targeting colorectal cancer are employed diagnostically, we have been able to demonstrate detection of colorectal cancer at its inception as a premalignant lesion, such that genotypic features can be identified before the phenotypic appearance of cancer can be noted.